Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 1/20 | 0.33 |
| ▸ | CD40LG | P29965 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.32 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.30 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619153 | 0.92 | CD40 (0.32) | CD40CD40LGPTPN11ENPP2SUMO2 | |
| SCHEMBL13433122 | 0.90 | CD40 (0.31) | CD40CD40LGPTPN11ENPP2 | |
| SCHEMBL13619137 | 0.88 | ENPP2 (0.30) | ENPP2SUMO2SUMO1SENP7SENP2 | |
| SCHEMBL13432908 | 0.86 | ENPP2 (0.31) | ENPP2 | |
| SCHEMBL13619142 | 0.85 | — | — | |
| SCHEMBL13619150 | 0.84 | THRB (0.39) | CD40CD40LGPTPN11ENPP2 | |
| SCHEMBL13619167 | 0.82 | ENPP2 (0.33) | ENPP2 | |
| SCHEMBL13619145 | 0.82 | — | — | |
| SCHEMBL13619132 | 0.82 | THRB (0.43) | PTPN11ENPP2 | |
| SCHEMBL13619163 | 0.82 | ENPP2 (0.40) | CD40CD40LGENPP2SUMO2SUMO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619074-B2 | Reactive dyestuff with N,N-dialkylamino bridge group | EVERLIGHT USA, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090176972-A1 | Novel reactive dyestuff with N,N-dialkylamino bridge group | EVERLIGHT USA, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176972-A1 | Novel reactive dyestuff with N,N-dialkylamino bridge group | SRM, PADI1, NOS1 | CD40 3394/4885CD40LG 2274/4885PTPN11 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.